Abstract
A series of novel derivatives containing triazolo-thiadiazole moiety have been synthesized by structural modifications on a lead disruptor of telomeric silencing 1-like (DOT1L) inhibitor 8. All the compounds have been evaluated for their DOT1L inhibitory activities at the concentration of 50 μmol/L. The results showed that the tested compounds showed certain DOT1L inhibitory activities. Among them, N, N-dimethyl-4-(6-methyl-[1, 2, 4]triazolo[3, 4-b] [1, 3, 4]thiadiazol-3-yl)aniline (14b) and (R)-tert-butyl (1-((3-(4-(dimethylamino)phenyl)-[1, 2, 4]triazolo[3, 4-b] [1, 3, 4]thiadiazol-6-yl)methyl)-piperidin-3-yl)carba- mate (16a) were the best ones with IC50 values of 7.37 and 7.84 μmol/L, respectively, near that of the positive control 8. The structure-activity analysis showed that when the triazolo-thiadiazole moiety occupied the binding-site of S-adenosylmethionine (SAM) in DOT1L and R1 group was 4-N, N-dimethyl, the hydrophobic substituents as the tailed R2 groups would be accommodated into the DOT1L binding site, and the sizes of the substituents seemed no effects on their DOT1L inhibitory activities of the compounds.
| Translated title of the contribution | Structural Modifications of the Triazolo-thiadiazole Derivatives as DOT1L Inhibitors and Their Activities |
|---|---|
| Original language | Chinese (Traditional) |
| Pages (from-to) | 1345-1354 |
| Number of pages | 10 |
| Journal | Chinese Journal of Organic Chemistry |
| Volume | 40 |
| Issue number | 5 |
| DOIs | |
| State | Published - 1 May 2020 |
| Externally published | Yes |